Literature DB >> 30571575

Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease.

Shuaib M Abdullah1,2, Laura F Defina3, David Leonard3, Carolyn E Barlow3, Nina B Radford4, Benjamin L Willis3, Anand Rohatgi1, Darren K McGuire1, James A de Lemos1, Scott M Grundy1,2, Jarett D Berry1, Amit Khera1.   

Abstract

BACKGROUND: The associations of low-density lipoprotein cholesterol (LDL-C) with cardiovascular disease (CVD) and coronary heart disease mortality in an exclusively low estimated 10-year risk group are not well delineated. We sought to determine the long-term associations of various LDL-C and non-high-density lipoprotein cholesterol (HDL-C) thresholds and CVD and coronary heart disease mortality in a large, low 10-year risk cohort.
METHODS: The study sample included participants of the CCLS (Cooper Center Longitudinal Study) without a history of CVD or diabetes mellitus and defined as low risk (<7.5%) for 10-year atherosclerotic CVD events at baseline based on Pooled Cohort Risk Assessment Equations. The associations of fasting LDL-C and non-HDL-C with CVD mortality were tested with Cox proportional hazards models.
RESULTS: In 36 375 participants (72% men, median age 42) followed for a median of 26.8 years, 1086 CVD and 598 coronary heart disease deaths occurred. Compared with LDL-C <100 mg/dL, LDL-C categories 100 to 129 mg/dL, 130 to 159 mg/dL, 160 to 189.9 mg/dL, and ≥190 mg/dL were associated with a significantly higher risk of CVD death, with hazard ratios of 1.4 (95% CI, 1.1-1.7), 1.3 (95% CI, 1.1-1.6), 1.9 (95% CI, 1.5-2.4), and 1.7 (95% CI, 1.3-2.3), and mean reductions in years free of CVD death of 1.8, 1.1, 4.3, and 3.9, respectively. After adjustment for atherosclerotic CVD risk factors, LDL-C categories 160 to 189 mg/dL and ≥190 mg/dL remained independently associated with CVD mortality, with hazard ratios of 1.7 (95% CI, 1.4-2.2) and 1.5 (95% CI, 1.2-2.1), respectively. In multivariable-adjusted models using non-HDL-C <130 mg/dL as the reference, non-HDL-C 160 to 189 mg/dL, 190 to 219 mg/dL, and ≥220 mg/dL were significantly associated with CVD death, with hazard ratios of 1.3 (95% CI, 1.1-1.6), 1.8 (95% CI, 1.4-2.2), and 1.5 (95% CI, 1.2-2.0), respectively. Restricting the cohort to those with 10-year risk <5% did not diminish the associations of LDL-C and non-HDL-C with CVD mortality.
CONCLUSIONS: In a low 10-year risk cohort with long-term follow-up, LDL-C and non-HDL-C ≥160 mg/dL were independently associated with a 50% to 80% increased relative risk of CVD mortality. These findings may have implications for future cholesterol treatment paradigms.

Entities:  

Keywords:  long-term follow-up; low-density lipoprotein; primary prevention

Mesh:

Substances:

Year:  2018        PMID: 30571575     DOI: 10.1161/CIRCULATIONAHA.118.034273

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  46 in total

Review 1.  New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease.

Authors:  Julius L Katzmann; Ulrich Laufs
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

2.  Low-Density Lipoprotein Cholesterol: Is 160 the New 190?

Authors:  Salim S Virani; Christie M Ballantyne
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

3.  Low LDL-C levels are associated with risk of mortality in a Chinese cohort study.

Authors:  Jie-Ming Lu; Meng-Yin Wu; Zong-Ming Yang; Yao Zhu; Die Li; Zhe-Bin Yu; Peng Shen; Meng-Ling Tang; Ming-Juan Jin; Hong-Bo Lin; Li-Ming Shui; Kun Chen; Jian-Bing Wang
Journal:  Endocrine       Date:  2021-05-14       Impact factor: 3.633

Review 4.  Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management.

Authors:  Amanda Bergamin; Evangeline Mantzioris; Giordana Cross; Permal Deo; Sanjay Garg; Alison M Hill
Journal:  Pharmaceut Med       Date:  2019-08

5.  The Association Between Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts.

Authors:  Michael G Nanna; Ann Marie Navar; Daniel Wojdyla; Eric D Peterson
Journal:  J Am Geriatr Soc       Date:  2019-08-14       Impact factor: 5.562

6.  Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.

Authors:  Karol M Pencina; George Thanassoulis; John T Wilkins; Ramachandran S Vasan; Ann Marie Navar; Eric D Peterson; Michael J Pencina; Allan D Sniderman
Journal:  J Am Coll Cardiol       Date:  2019-07-09       Impact factor: 24.094

7.  The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines.

Authors:  Anandita Agarwala; Jing Liu; Christie M Ballantyne; Salim S Virani
Journal:  Curr Cardiovasc Risk Rep       Date:  2019-05-23

8.  MicroRNA-33-5p inhibits cholesterol efflux in vascular endothelial cells by regulating citrate synthase and ATP-binding cassette transporter A1.

Authors:  Qiong Xie; Jianqiang Peng; Ying Guo; Feng Li
Journal:  BMC Cardiovasc Disord       Date:  2021-09-13       Impact factor: 2.298

9.  Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns.

Authors:  Fahamina Ahmed; Shelby Gross; Samah Hammad; Candice Wilson; George Nawas; Batool Zeini
Journal:  Am Health Drug Benefits       Date:  2021-12

10.  Prospective Study on Plasma MicroRNA-4286 and Incident Acute Coronary Syndrome.

Authors:  Miaoyan Shen; Xuedan Xu; Xuezhen Liu; Qiuhong Wang; Wending Li; Xiaomin You; Rong Peng; Yu Yuan; Pinpin Long; Rundong Niu; Handong Yang; Xiang Cheng; An Pan; Robert M Tanguay; Xiaomin Zhang; Meian He; Chaolong Wang; Liming Liang; Tangchun Wu
Journal:  J Am Heart Assoc       Date:  2021-03-10       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.